Search This Blog

Tuesday, October 9, 2018

Private equity interest in orthopedic practices expected to balloon


Orthopedic practices haven’t cozied up with private equity firms quite as readily as their peers in, say, dermatology and ophthalmology, but a new report says that’s all changing.
The next five years will see a flurry of investment from private equity into orthopedic practices, deals that trigger further acquisitions with other practices to consolidate local or regional markets, according to the healthcare investment bank Edgemont Capital.
Jeff Swearingen, Edgemont’s co-founder and a managing director with the firm, said he’s aware of four or five orthopedic practices that are currently pursuing initial investments from private equity.
Physicians are warming to consolidation to counter pressures from managed care and to gain negotiating leverage with payers, Swearingen said. Physician practices with size and scale are better-positioned to counter the industry forces compared with their smaller, independent counterparts, he said.
“I think physicians are becoming increasingly aware of that dynamic,” he said.
The trend is being driven largely by two factors: the migration of hip and knee replacements to less expensive outpatient settings and the dramatic increase in the volume of such procedures, said Dr. Nathan Every, general partner with Frazier Healthcare Partners, a private equity investment firm that along with Princeton Ventures raised equity financing for the Core Institute, a group of 67 physicians that provide musculoskeletal and neurological care.
“There is greater efficiency and greater ability basically to do more better quality and cheaper joint reconstruction through physician-led organizations,” he said. “It’s pretty interesting. People are really thinking about how to do outpatient joints better, faster and cheaper.”
Edgemont’s report lists recent private equity investments in orthopedic practices, including Varsity Healthcare Partners’ investment in The Orthopedic Institute, an integrated orthopedic surgical care and ancillary patient treatment services provider in North Central Florida. The deal is expected to help the Institute aggressively grow its clinical footprint across Florida through a combination of acquisitions and accelerated recruitment efforts, Edgemont wrote.
Southeastern Spine Institute, the largest medical practice in South Carolina, was acquired last year in a private equity deal led by Candescent Partners. The practice has 16 physicians and 31 total providers, according to Edgemont’s report. The report also mentions the acquisition of Atlantic NeuroSurgical Specialists, a group that specializes in complex brain disorders using advanced technologies, by the private investment firm Lorient Capital, a deal that has not yet been announced.
Private equity partners tend to be hands off when it comes to how doctors practice medicine, but heavily involved on the financial side of the practice, especially when it comes to increasing infrastructure and adding more practices, Swearingen said.
“The practice has to be open to and embrace that opportunity for growth, if they’re not interested in embracing that growth, then there will be some level of conflict with their new partner,” he said.
For physicians who aspire to hold an ownership stake in the booming outpatient hip and knee replacement market, private equity can provide the necessary capital, Every said. Getting into the business is not cheap and requires a great deal of infrastructure, especially if physicians plan to use robotics, he said.
Dr. Jack Bert, chair of the American Academy of Orthopaedic Surgeons’ practice management and rehabilitation program committee, said while a private equity buy-out can provide a huge boost in capital, some physicians have subsequently found they lost control of the business side of their practice. Depending on how the deal was structured, the investment firm can take total control over the business direction of the group. That said, practices are being purchased for multiples of practices’ earnings, and Bert said it makes sense especially for older physicians.
“If you’re older, it’s phenomenal because you’ll make a fortune as you exit practice,” he said.
On the flip side, Bert said he’s seen lots of orthopedic practices get bought by health systems that take over control of how they practice medicine, which private equity tends not to touch.
“If the hospital system buys you out, you lose total control of your practice,” he said.
Bert said hospitals control where physicians practice, when they practice and the volume of patients they see, among other factors.
“Which is worse for the doctor? There’s no question the hospital buyouts are worse,” he said.

CMS schedules HealthCare.gov downtime during open enrollment


HealthCare.gov will again be taken offline for maintenance for a maximum of 60 hours during the upcoming open enrollment for Affordable Care Act exchange coverage, the CMS announced Tuesday.
Consumers may not be able to select a plan from the federally operated marketplace each Sunday between 12 a.m. and 12 p.m. ET, except on Dec. 9, the final Sunday of open enrollment. The CMS said the scheduled downtime, which is the same as last year’s, is during periods when HealthCare.gov sees the lowest traffic.
While the CMS alloted 60 hours total for maintenance, it said the 2018 open enrollment’s actual downtime totaled 21.5 hours. Last year, some observers criticized the Trump administration for what they considered excessive maintenance periods meant to undermine the healthcare exchanges. Open enrollment for 2019 coverage kicks off Nov. 1 and lasts until Dec. 15 in most states.

Healthcare companies soak up $23 billion in venture capital funding


U.S. healthcare companies had soaked up $23.4 billion this year in venture capital funding as of Sept. 30, already well surpassing the sector’s funding in all of 2017, and making up nearly 28% of total U.S. venture capital funding so far in 2018.
That’s according to Pitchbook’s quarterly report examining venture capital spending in the third quarter of 2018. Last year, healthcare services and systems, healthcare devices and supplies and pharma and biotech amassed $20.5 billion in venture capital funding, with pharma and biotech capturing far and away the largest share of those dollars. Pharma and biotech has made up 62% of venture capital funding so far in 2018.
Across all sectors, the $84.3 billion in deal volume amassed by the end of the third quarter had already surpassed 2017’s full-year funding of $82 billion. Roughly 6,500 deals had closed as of Sept. 30, putting this year on track to match the nearly 9,300 deals closed in 2017, according to Pitchbook.
Pitchbook highlighted a trend it calls the new normal: a lot of money flowing into fewer, larger deals. Case in point: The number of deals whose value exceeded $50 million reached 378 rounds as of the third quarter of 2018, already surpassing 292 such deals in all of 2017.
“The trend of high concentration of capital into fewer, larger investments has solidified into the status quo for the U.S. VC ecosystem,” the report’s authors wrote.
The first three quarters of this year have seen the rise of so-called unicorns, or startups valued at more than $1 billion. Pitchbook counted 39 such deals and nearly $8 billion raised in the third quarter alone. Unicorns are fueling an upsurge in “mega-rounds” of $100 million or more, the number of which has grown 39% over 2017. One example is the at-home fitness equipment maker Peloton, which raised the largest deal in the quarter, valued at $550 million. Pitchbook noted that consumer-focused companies captured nearly 22% of mega-deal capital in the third quarter.
Such mega-deals aren’t always a good thing, the report’s authors wrote.
“Mega-deals can concentrate risk in fewer companies, and rampant capital availability enables overcapitalization and potentially reckless spending by companies in pursuit of growth,” the report said.
On the flip side, the number of deals involving early-stage companies saw a double-digit decline in the third quarter, a slowdown that was even more pronounced among angel and seed deals, where activity fell 26.5% between the second and third quarters.
Jon Norris, a managing director with Silicon Valley Bank, a contributor to Pitchbook’s report, said he’s watched the amount of money going into Series A deals, a company’s first round of venture capital funding, balloon over time. In the past, $25 million was a large Series A, but that’s grown over the last couple of years to between $75 million and $100 million.
“And now we’re seeing $200 million Series As,” he said.
Life sciences, a category that includes pharma and devices, drew fewer, yet larger early-stage deals than the artificial intelligence sector during the third quarter, attracting 109 deals and $2.5 billion in funding, down from its peak of $3.4 billion in the first quarter, according to the report.
Norris, who focuses mainly on the life sciences sector, said biopharma continues to see strong growth in the amount of capital going into deals, while devices are by and large staying stable.
“I think there’s a tale of two cities on this,” he said. “Biopharma is just going gangbusters, and it’s on pace for a record-breaking year. Devices is the stable, well-performing sector. Lots of exits and continued investment, but not what we’re seeing in these other sectors.”

Eisai to Present Data in a Variety of Advanced Cancers at ESMO 2018 Congress


New data on tumor growth rate and lenvatinib efficacy in radioiodine-refractory differentiated thyroid cancer to be presented in oral Proffered Paper session on Monday, Oct. 22 at 3:09 p.m. CEST

Eisai Inc. announced today the presentation of six abstracts featuring data and analyses on its cancer treatments at the European Society of Medical Oncology (ESMO) 2018 Congress taking place in Munich from October 19-23. The results to be presented highlight new data for the company’s oncology agents, lenvatinib (marketed as LENVIMA®) and eribulin (marketed as HALAVEN®) for approved and investigational uses, respectively.

Presentations of interest include:
  • An oral presentation on tumor growth rate and lenvatinib efficacy in radioiodine-refractory differentiated thyroid cancer.
  • Correlative analyses of serum biomarkers and efficiency outcomes for lenvatinib, everolimus and the combination of these two agents in patients with metastatic renal cell carcinoma.
  • A final analysis of serum biomarkers from a Phase III study of lenvatinib vs. sorafenib in unresectable hepatocellular carcinoma.
  • Early results of a Phase Ib/II study on the combination of eribulin and PEGPH20 (PEGylated recombinant human hyaluronidase) in patients with HER2-negative, high hyaluronan metastatic breast cancer.
“Our data at ESMO include insights into the potential of lenvatinib and eribulin both as monotherapies and in combination with other agents across a variety of difficult-to-treat cancers,” said Alton Kremer, MD, PhD, Chief Clinical Officer and Chief Medical Officer, Oncology Business Group at Eisai. “As part of our human health care mission and dedication to patient access, we are committed to continually exploring ways to improve understanding of Eisai’s oncology treatments for the medical community and the patients impacted by these advanced cancers.”
This release discusses investigational compounds that are not Food and Drug Administration (FDA)-approved and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

DA Davidson Starts Nu Skin Enterprises (NUS) at Buy


DA Davidson analyst Linda Bolton Weiser initiates

Cowen Dives Into The Cannabis Industry: ‘Large Market Opportunities’


Cowen has revisited its models for cannabis companies Tilray Inc. TLRY 7.89% and Canopy Growth Corp. CGC 3.39% amid volatility in the emerging market.

The Analyst

Vivien Azer maintained an Outperform rating on both Canopy Growth and Tilray. The analyst raised the price target for Tilray from $62 to $172 and raised the price target for Canopy’s Toronto-traded shares from the U.S. dollar equivalent $57.17 to $63.35.
Tilray shares were down 7.91 percent at $128.92 at the time of publication Tuesday. Canopy Growth’s U.S.-traded shares were down 1.92 percent at $49.44.

Long-Term Opportunity

The well-capitalized market has rapidly evolved and has four key verticals: adult use, beauty and nutraceuticals, pharmaceuticals and over-the-counter pain and sleep uses, according to Cowen.
“We believe that all four of these verticals represent large market opportunities, and CPG veterans are beginning to embrace the broad market potential for cannabis as a global, multidimensional category given the talent migration to cannabis,” Azer said in a Tuesday note. (See her track record here.)

Consumer Trends

The valuation of both Canopy Growth and Tilray is rooted in an analysis of overall consumer trends, the analyst said. For example, there have been five distinct cycles in alcohol consumption over the last 80 years, she said.
White spirits like vodka and gin have gained substantial market share over brown spirits like bourbon and whiskey, she said. Beer and spirits cycles tend to move in tandem, and should likely increase with the reverse bourbon trends, in Azer‘s view.
“As bourbon trends have reversed, we saw an increased shift to import and craft beer as consumers reverted back to drinking more flavorfully and expensively.”

Market Opportunity

The cannabis opportunity is far broader than what’s created by the Canadian legalization of cannabis Oct. 17, Azer said. “Rather, we believe this is the first step toward the establishment of cannabis as a key functional ingredient touching multiple consumer categories.”

Volatility

Cannabis investing is still new and the industry is still taking shape, the analyst said. Consequently, volatility is a natural occurrence and not unique to this particular industry at this stage of development, she said.

Valuation

When considering cannabis valuations, long-term durable growth must be considered, Azersaid.
“We caution that these valuation parameters and price targets are based on what we estimate about these companies today,” Azer said.
“In the fast-evolving cannabis sector, dynamics can change quickly. The most recent example is beverage companies taking stakes in cannabis companies. While that dynamic was not completely unexpected, the timing of it perhaps was, and served as a fresh catalyst for the stocks.”

Neurocrine, Jnana in Collaboration on Central Nervous System Disorders


Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Jnana Therapeutics Inc. today announced that they have entered into a research collaboration aimed at discovering novel small molecule therapeutics for multiple targets for central nervous system (CNS) disorders. The collaboration will leverage Jnana’s proprietary drug discovery platform across the solute carrier (SLC) family of transporters and Neurocrine’s research and development expertise in CNS disorders to advance new medicines.
Under the terms of the agreement, Neurocrine and Jnana will work jointly to identify novel compounds, after which time Neurocrine will be responsible for further lead optimization, and the development and commercialization of any potential therapies arising from the collaboration. Neurocrine will also provide Jnana with one-time access to a subset of its compound library for Jnana to screen for hits on a select number of non-CNS targets. As part of the collaboration, Jnana will receive an up-front payment and committed research funding to support discovery efforts. In addition, Jnana is eligible to receive milestone payments and royalties based upon products resulting from this collaboration.
“We are excited to partner with Jnana Therapeutics as their proprietary drug discovery platform complements our commitment to neuroscience innovation,” said Dimitri E. Grigoriadis, Ph.D., Chief Research Officer. “At Neurocrine, we have extensive experience in developing new medicines targeted to the solute carrier family of transporters, such as VMAT2, which led to the discovery of valbenazine. We look forward to working with Jnana to discover important new medicines for patients with central nervous system disorders.”
“We are very pleased to be entering into this strategic collaboration with Neurocrine Biosciences. Their deep knowledge in neuroscience and of the solute carrier family of transporters makes them an ideal partner as we work together to discover new medicines to treat CNS disorders,” said Joel Barrish, Ph.D., Cofounder and Chief Scientific Officer at Jnana. “This collaboration also demonstrates Neurocrine’s confidence in Jnana’s proprietary small molecule platform to address therapeutic targets rapidly and comprehensively across the SLC transporter family.”